FDA Approves Intellis Device for Intractable Pain

Wednesday, September 20, 2017

The FDA has approved the Intellis platform (Medtronic) for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems and can power the EvolveSM workflow*, which standardizes guidance and balances high-dose (HD) and low-dose (LD) therapy settings. The Intellis platform can record and track patient activity and is managed on the Samsung Galaxy Tab S2 tablet interface, enabling physicians to address the subjective and personal nature of chronic pain by monitoring progress and making modifications to better suit their patients' therapy needs. The Intellis platform also uses Medtronic's proprietary Overdrive(TM) battery technology to fully recharge the battery from empty to full in approximately one hour. Additionally, physicians can now estimate recharge intervals based on therapy settings.

Next Story


You must be logged in to leave a comment.